Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function

Sebastián Figueroa-Bonaparte, Sonia Segovia, Jaume Llauger, Izaskun Belmonte, Irene Pedrosa, Aída Alejaldre, Mercè Mayos, Guillermo Suárez-Cuartín, Eduard Gallardo, Isabel Illa, Jordi Díaz-Manera, Spanish Pompe Study Group, Sebastián Figueroa-Bonaparte, Sonia Segovia, Jaume Llauger, Izaskun Belmonte, Irene Pedrosa, Aída Alejaldre, Mercè Mayos, Guillermo Suárez-Cuartín, Eduard Gallardo, Isabel Illa, Jordi Díaz-Manera, Spanish Pompe Study Group

Abstract

Objectives: Enzyme replacement therapy has shown to be effective for childhood/adult onset Pompe disease (AOPD). The discovery of biomarkers useful for monitoring disease progression is one of the priority research topics in Pompe disease. Muscle MRI could be one possible test but the correlation between muscle MRI and muscle strength and function has been only partially addressed so far.

Methods: We studied 34 AOPD patients using functional scales (Manual Research Council scale, hand held myometry, 6 minutes walking test, timed to up and go test, time to climb up and down 4 steps, time to walk 10 meters and Motor Function Measure 20 Scale), respiratory tests (Forced Vital Capacity seated and lying, Maximun Inspiratory Pressure and Maximum Expiratory Pressure), daily live activities scales (Activlim) and quality of life scales (Short Form-36 and Individualized Neuromuscular Quality of Life questionnaire). We performed a whole body muscle MRI using T1w and 3-point Dixon imaging centered on thighs and lower trunk region.

Results: T1w whole body muscle MRI showed a homogeneous pattern of muscle involvement that could also be found in pre-symptomatic individuals. We found a strong correlation between muscle strength, muscle functional scales and the degree of muscle fatty replacement in muscle MRI analyzed using T1w and 3-point Dixon imaging studies. Moreover, muscle MRI detected mild degree of fatty replacement in paraspinal muscles in pre-symptomatic patients.

Conclusion: Based on our findings, we consider that muscle MRI correlates with muscle function in patients with AOPD and could be useful for diagnosis and follow-up in pre-symptomatic and symptomatic patients under treatment.

Take home message: Muscle MRI correlates with muscle function in patients with AOPD and could be useful to follow-up patients in daily clinic.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Distribution of muscle weakness in…
Fig 1. Distribution of muscle weakness in the cohort of AOPD participating in the study.
The heatmap showed the MRC value for all muscles studied. Hip extension and flexion and trunk extension and flexion were the most weak impaired movements of the patients. In contrast, we did not observe distal weakness involving the lower or the upper limbs.
Fig 2. Representation of score of muscle…
Fig 2. Representation of score of muscle infiltration observed in T1 imaging in each muscle of every patient by heatmaps.
(A) Heatmap including muscles of the head, upper limbs and trunk. (B) Heatmap including muscles of the pelvis and lower limbs. In each heatmap, patients (rows) are ordered according to hierarchical clustering with increasing grading in infiltration severity from the top to the bottom. Muscles (columns) are ordered according to dendrogram (upper part of the figures). The score of a muscle in a patient is indicated by the colour of the square in the interaction between the patient and that muscle. The darker the square, the more intense the fatty infiltration of that muscle is.
Fig 3. T1w Muscle MRI of patients…
Fig 3. T1w Muscle MRI of patients with Pompe disease.
We observed mild fatty infiltration in muscles of hyperCKemia patients: Tongue (Tin A), paraspinal muscles (Ps in B), lateral abdominal muscles (Ab in B) and rectus abdominis (RA in C) and in adductor major muscles (AM in D). The fatty infiltration in symptomatic patients was more evident (E-L). The muscles more commonly involved were tongue (T in E), subscapularis (Sc in F), latissimus dorsi (LD in G), the abdominal (Ab in H) and paraspinal muscles (Ps in H), the Gluteus minor (GMn in I), medius (GMe in J) and maximus (GMa in J), the muscles of the pelvic floor such as the Externus Obturator (Obt. Ext. in K), the posterior muscles of the thighs (Post in L), and the vasti muscles including vastus intermedius (VI in M) and vastus lateralis (VL in M). We observed involvement of rectus femoris and gracillis in advanced patients (RF and Gra in N). Muscles of the lower legs were commonly spared (O).
Fig 4. Analysis of fatty infiltration in…
Fig 4. Analysis of fatty infiltration in muscle MRIs.
(A) We observed significant differences in the percentage of fatty infiltration quantified using 3-point Dixon technique in most of the muscles between symptomatic (red bars) and hyperckemia patients (green bars). We compared both groups using the Student T test (single asterisk for differences with pSemitendinosus, Semimembranosus, Biceps Long Head and Biceps Short Head). Pompe 14 patients (hyperckemia patient) had higher strength in knee flexion measured with the myometer than patient 1 (symptomatic patient). We observed predominant fatty infiltration in the posterior muscles of the thighs producing decreased strength in the knee flexion test. (C) There was a strong correlation between knee flexion strength and the degree of muscle fatty infiltration calculated both using 3-point Dixon (left) and the Mercuri scale (right). Green dots showed values of hyperckemia patients, while red ones represent values of symptomatic patients. (D) We found a strong correlation between 3 point Dixon analysis and Mercuri score. We have represented the correlation between the quantification of fat infiltration using the mean Mercuri score and the mean 3-point Dixon score of the posterior thigh muscles (Semitendinosus, Semimembranosus, Biceps Long Head and Biceps Short Head). RF: rectus femoris; VL: vastus laterallis; VM: vastus medialis; VI: vastus intermedius; AM: adductor major; AL: adductor longus; BSH: biceps short head; BLH: biceps long head; ST: semitendinosus; SM: semimembranosus; SA: sartorius; GR: gracillis; MU: multifidus; LO: longissimus; IL: iliocostalis; QU: quadratus femoris; PS: psoas; ABD: lateral abdominal muscles; RA: rectus abdominis.
Fig 5. Correlation between Muscle MRI and…
Fig 5. Correlation between Muscle MRI and Functional scales.
Patient 30 is a 43 years old man with mild infiltration of pelvic and lower limbs muscles with minor functional impairment. Patient 22 is a 40 years old lady with moderate involvement of trunk, pelvic and thighs muscles. She was able to perform most of her daily live activities with no major problems but her clinical examination showed moderate weakness of pelvic muscles. Patient 2 is a 48 years old lady with a severe involvement of muscle producing severe weakness and notably impairing her daily live activities.

References

    1. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008;372(9646):1342–53. 10.1016/S0140-6736(08)61555-X .
    1. Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Laboratory investigation; a journal of technical methods and pathology. 2006;86(12):1208–20. 10.1038/labinvest.3700484 .
    1. Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L, et al. Diagnosis of glycogenosis type II. Neurology. 2008;71(23 Suppl 2):S4–11. 10.1212/WNL.0b013e31818da91e .
    1. Gungor D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SC, et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. Journal of inherited metabolic disease. 2015. 10.1007/s10545-015-9889-6 .
    1. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. The New England journal of medicine. 2010;362(15):1396–406. 10.1056/NEJMoa0909859 .
    1. van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Molecular genetics and metabolism. 2012;107(3):456–61. 10.1016/j.ymgme.2012.09.015 .
    1. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. Journal of neurology. 2013;260(4):951–9. 10.1007/s00415-012-6636-x .
    1. Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health technology assessment. 2012;16(39):1–543. 10.3310/hta16390 .
    1. Barba-Romero MA, Barrot E, Bautista-Lorite J, Gutierrez-Rivas E, Illa I, Jimenez LM, et al. Clinical guidelines for late-onset Pompe disease. Revista de neurologia. 2012;54(8):497–507. .
    1. Gutierrez-Rivas E, Illa I, Pascual-Pascual SI, Perez-Lopez J, Vilchez-Padilla JJ, Bautista-Lorite J, et al. [Guidelines for monitoring late-onset Pompe disease]. Revista de neurologia. 2015;60(7):321–8. .
    1. Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle & nerve. 2012;45(3):319–33. 10.1002/mus.22329
    1. Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. Journal of magnetic resonance imaging: JMRI. 2007;25(2):433–40. 10.1002/jmri.20804 .
    1. Paradas C, Llauger J, Diaz-Manera J, Rojas-Garcia R, De Luna N, Iturriaga C, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology. 2010;75(4):316–23. 10.1212/WNL.0b013e3181ea1564 .
    1. Hollingsworth KG. Quantitative MRI in muscular dystrophy: An indispensable trial endpoint? Neurology. 2014;83(11):956–7. 10.1212/WNL.0000000000000785 .
    1. Straub V, Carlier PG, Mercuri E. TREAT-NMD workshop: pattern recognition in genetic muscle diseases using muscle MRI: 25–26 February 2011, Rome, Italy. Neuromuscular disorders: NMD. 2012;22 Suppl 2:S42–53. 10.1016/j.nmd.2012.08.002 .
    1. Udd B. Distal myopathies—new genetic entities expand diagnostic challenge. Neuromuscular disorders: NMD. 2012;22(1):5–12. 10.1016/j.nmd.2011.10.003 .
    1. Morrow JM, Sinclair CD, Fischmann A, Machado PM, Reilly MM, Yousry TA, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. The Lancet Neurology. 2016;15(1):65–77. 10.1016/S1474-4422(15)00242-2
    1. Wary C, Azzabou N, Giraudeau C, Le Louer J, Montus M, Voit T, et al. Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy. NMR in biomedicine. 2015;28(9):1150–62. 10.1002/nbm.3352 .
    1. Fischer D, Kley RA, Strach K, Meyer C, Sommer T, Eger K, et al. Distinct muscle imaging patterns in myofibrillar myopathies. Neurology. 2008;71(10):758–65. 10.1212/01.wnl.0000324927.28817.9b
    1. Diaz-Manera J, Alejaldre A, Gonzalez L, Olive M, Gomez-Andres D, Muelas N, et al. Muscle imaging in muscle dystrophies produced by mutations in the EMD and LMNA genes. Neuromuscular disorders: NMD. 2015. 10.1016/j.nmd.2015.10.001 .
    1. Carlier RY, Laforet P, Wary C, Mompoint D, Laloui K, Pellegrini N, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. Neuromuscular disorders: NMD. 2011;21(11):791–9. 10.1016/j.nmd.2011.06.748 .
    1. Diaz-Manera J, Llauger J, Gallardo E, Illa I. Muscle MRI in muscular dystrophies. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases. 2015;34(2–3):95–108.
    1. Bonati U, Hafner P, Schadelin S, Schmid M, Naduvilekoot Devasia A, Schroeder J, et al. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscular disorders: NMD. 2015;25(9):679–85. 10.1016/j.nmd.2015.05.006 .
    1. Horvath JJ, Austin SL, Case LE, Greene KB, Jones HN, Soher BJ, et al. Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease. Muscle & nerve. 2015;51(5):722–30. 10.1002/mus.24437 .
    1. Ma J. Dixon techniques for water and fat imaging. Journal of magnetic resonance imaging: JMRI. 2008;28(3):543–58. 10.1002/jmri.21492 .
    1. Ravaglia S, Pichiecchio A, Ponzio M, Danesino C, Saeidi Garaghani K, Poloni GU, et al. Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. Journal of inherited metabolic disease. 2010;33(6):737–45. 10.1007/s10545-010-9204-5 .
    1. Arpan I, Willcocks RJ, Forbes SC, Finkel RS, Lott DJ, Rooney WD, et al. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology. 2014;83(11):974–80. 10.1212/WNL.0000000000000775
    1. Alejaldre A, Diaz-Manera J, Ravaglia S, Tibaldi EC, D'Amore F, Moris G, et al. Trunk muscle involvement in late-onset Pompe disease: study of thirty patients. Neuromuscular disorders: NMD. 2012;22 Suppl 2:S148–54. 10.1016/j.nmd.2012.05.011 .
    1. Wokke BH, Bos C, Reijnierse M, van Rijswijk CS, Eggers H, Webb A, et al. Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients. Journal of magnetic resonance imaging: JMRI. 2013;38(3):619–24. 10.1002/jmri.23998 .
    1. Carlier PG, Azzabou N, de Sousa PL, Hicks A, Boisserie JM, Amadon A, et al. Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients. Journal of inherited metabolic disease. 2015;38(3):565–72. 10.1007/s10545-015-9825-9
    1. Pichiecchio A, Poloni GU, Ravaglia S, Ponzio M, Germani G, Maranzana D, et al. Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful? Muscle & nerve. 2009;40(1):122–5. 10.1002/mus.21304 .
    1. Gruhn KM, Heyer CM, Guttsches AK, Rehmann R, Nicolas V, Schmidt-Wilcke T, et al. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy. Molecular genetics and metabolism reports. 2015;3:58–64. 10.1016/j.ymgmr.2015.03.010

Source: PubMed

3
Iratkozz fel